SCHEMBL1496750

SCHEMBL1496750

Cc1ccc(OCC(C)O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.67
USP2 O75604 1/20 0.56
TSHR P16473 1/20 0.56
MAPT P10636 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
RECQL P46063 1/20 0.49
KMT2A Q03164 1/20 0.49
WDR5 P61964 1/20 0.47
NPC1 O15118 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14570065 1.00 LMNA (0.67) LMNAUSP2TSHRMAPTNPSR1
SCHEMBL5949941 0.91 LMNA (0.78) LMNAUSP2TSHRMAPTNPSR1
SCHEMBL14447568 0.91 LMNA (0.56) LMNAUSP2TSHRMAPTNPSR1
SCHEMBL14189198 0.84 USP2 (0.68) LMNAUSP2TSHRMAPTNPSR1
Toluene SCHEMBL28503513 0.84 LMNA (0.73) LMNAMAPTNPSR1KDM4EMEN1
SCHEMBL10922516 0.83 LMNA (0.67) LMNAMEN1CYP1A2CYP2D6CYP2C19
SCHEMBL28631164 0.83 LMNA (0.67) LMNAUSP2TSHRMAPTNPSR1
SCHEMBL1496625 0.83 LMNA (0.67) LMNATSHRMAPTKDM4EMEN1
SCHEMBL2231003 0.82 TSHR (0.50) LMNAUSP2TSHRMAPTNPSR1
SCHEMBL24352249 0.81 LMNA (0.64) LMNAMAPTNPSR1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893588-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2008-03-05 EP claimed
WO-2006135826-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-12-21 WO claimed
US-20250081832-A1 METHOD FOR FORMING AN ORGANIC ELEMENT OF AN ELECTRONIC DEVICE MERCK PATENT GMBH (DE) 2025-03-06 US disclosed
US-12063847-B2 Method for forming an organic element of an electronic device MERCK PATENT GMBH (DE) 2024-08-13 US disclosed
US-11538992-B2 Formulation of an organic functional material MERCK PATENT GMBH (DE) 2022-12-27 US disclosed
US-20220013724-A1 METHOD FOR FORMING AN ORGANIC ELEMENT OF AN ELECTRONIC DEVICE MERCK PATENT GMBH (DE) 2022-01-13 US disclosed
US-20210179634-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-06-17 US disclosed
US-20210177826-A1 ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-06-17 US disclosed
EP-3532565-B1 FORMULATION OF AN ORGANIC FUNCTIONAL MATERIAL MERCK PATENT GMBH (DE) 2021-04-21 EP disclosed
US-10723742-B2 Biphenyl compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-07-28 US disclosed
US-20200190175-A1 METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-06-18 US disclosed
EP-1178973-A2 NOVEL COMPOUNDS, THEIR USE AND PREPARATION Pharmacia AB (SE) 2002-02-13 EP disclosed
WO-2000076984-A2 NOVEL COMPOUNDS, THEIR USE AND PREPARATION BIOVITRUM AB (SE) 2000-12-21 WO disclosed
EP-0492615-B1 Process for producing biguanide derivative IDEMITSU KOSAN CO (JP) 1995-03-08 EP disclosed
US-5286905-A Heating hydrogen halide salt of phenoxyalkylamine with dicyandiamide in paraffinic hydrocarbon solvent IDEMITSU KOSAN COMPANY LIMITED (JP) 1994-02-15 US disclosed
EP-0492615-A1 Process for producing biguanide derivative IDEMITSU KOSAN COMPANY LIMITED (JP) 1992-07-01 EP disclosed
US-4388081-A CONTAINING PHENOXYALCOHOL AS ANTINKNOCK ADDITIVE PHILLIPS PETROLEUM COMPANY (US) 1983-06-14 US disclosed
US-4255152-A USING A DISPERSE DYE, WATER, AND AN ADDUCT OF ETHYLENE, PROPYLENE, OR STYRENE OXIDE AND A CYCLIC-SUBSTITUTED PHENOL; LEVELLING CIBA-GEIGY CORPORATION (US) 1981-03-10 US disclosed
US-4000315-A Cyclopropane esters for the control of mites ZOECON CORPORATION (US) 1976-12-28 US disclosed
US-3957849-A MITICIDES ZOECON CORPORATION (US) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210177826-A1 ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND KDM1B, KDM1A, DOT1L LMNA 1525/4885USP2 689/4885TSHR 2794/4885
US-10723742-B2 Biphenyl compound or salt thereof KDM1B, BMI1, HDAC1 LMNA 1369/4885USP2 1385/4885TSHR 4543/4885
US-20200190175-A1 METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 INMT, CARM1, KDM1B LMNA 420/4885USP2 203/4885TSHR 3555/4885
US-20210179634-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF KDM1B, KDM1A, HDAC1 LMNA 2070/4885USP2 1132/4885TSHR 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.